Lytix Biopharma aktie (LYTIX) | Pressmeddelande

Lytix Biopharma AS - New share capital registered

Cision • 23 Dec 17:26

Lytix Biopharma AS: Key information relating to potential subsequent offering

Cision • 17 Dec 08:05

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Cision • 17 Dec 08:05

Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed

Cision • 17 Dec 00:30

Lytix Biopharma – Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement

Cision • 16 Dec 17:09

Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid

Cision • 16 Dec 17:04

Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion

Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 ...

Cision • 21 Nov 15:48

Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization

Cision • 19 Nov 07:05

Lytix Biopharma: Invitation to Q3 2024 Results Presentation

Cision • 12 Nov 10:33

First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma

First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with ...

Cision • 06 Nov 22:23

Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals

Cision • 05 Nov 07:05

Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference

Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conferen...

Cision • 24 Oct 14:19

Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization

Cision • 29 Aug 08:05

Lytix Biopharma: Invitation to Q2 2024 Results Presentation

Cision • 23 Aug 08:05

PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy

PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patient...

Cision • 14 Aug 13:44

Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14

Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX...

Cision • 06 Aug 16:51

Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones

Cision • 30 May 07:03

Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024

Cision • 22 May 11:47

Lytix Biopharma – Minutes of Ordinary General Meeting

Cision • 14 May 14:29

Lytix Biopharma AS - New share capital registered

Cision • 13 May 15:16

Correction in the notice of Annual General Meeting in Lytix Biopharma AS

Cision • 03 May 16:39

Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024

Cision • 30 Apr 07:05

Lytix Biopharma AS: Annual Report for 2023

Cision • 30 Apr 07:00

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Cision • 26 Apr 16:06

Lytix Biopharma AS – Share issue pursuant to board authorisation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM,...

Cision • 26 Apr 15:49

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Cision • 25 Apr 17:13

Lytix Biopharma AS – Minutes of extraordinary general meeting and final results of share offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM,...

Cision • 25 Apr 16:18

Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity

Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportu...

Cision • 25 Apr 13:48

Lytix Biopharma AS – Preliminary results in the share offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM,...

Cision • 24 Apr 21:55

Lytix Biopharma AS - Last day of the Application Period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM,...

Cision • 24 Apr 07:00

Lytix Biopharma presents third quarter 2023 results

Cision • 09 Nov 2023 08:00

Lytix Biopharma presenting at major investor conferences in London and Stockholm in November

Cision • 08 Nov 2023 12:00

Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023

Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology compan...

Cision • 23 Oct 2023 08:02

Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’

Oslo, 17 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology compan...

Cision • 17 Oct 2023 08:00

Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published.

Oslo, 16 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology compan...

Cision • 16 Oct 2023 08:52

Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting

Oslo, 9 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company...

Cision • 09 Oct 2023 15:00

Lytix Biopharma presents first half and second quarter 2023 results

Building a Phase II evidence base Oslo, 31 August 2023.

Cision • 31 Aug 2023 08:00

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial

Oslo, 28 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company...

Cision • 28 Aug 2023 13:59

Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase 2 data with LTX-315

· Promising clinical results showed clearance of basal cell carcinoma lesions in 4 of 6 patients.

Cision • 11 Aug 2023 08:00

Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting

Oslo, 3 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,...

Cision • 03 Aug 2023 15:02

Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023.

Oslo, 20 July 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, ...

Cision • 20 Jul 2023 09:00

Börskollen

För dig med koll på börsen

Pressmeddelanden från Lytix Biopharma

Lytix Biopharma AS - New share capital registered

Lytix Biopharma AS: Key information relating to potential subsequent offering

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed

Lytix Biopharma – Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement

Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid

Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion

Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization

Lytix Biopharma: Invitation to Q3 2024 Results Presentation

First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma

Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals

Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference

Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization

Lytix Biopharma: Invitation to Q2 2024 Results Presentation

PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy

Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14

Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones

Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024

Lytix Biopharma – Minutes of Ordinary General Meeting

Lytix Biopharma AS - New share capital registered

Correction in the notice of Annual General Meeting in Lytix Biopharma AS

Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024

Lytix Biopharma AS: Annual Report for 2023

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Lytix Biopharma AS – Share issue pursuant to board authorisation

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Lytix Biopharma AS – Minutes of extraordinary general meeting and final results of share offering

Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity

Lytix Biopharma AS – Preliminary results in the share offering

Lytix Biopharma AS - Last day of the Application Period

Lytix Biopharma presents third quarter 2023 results

Lytix Biopharma presenting at major investor conferences in London and Stockholm in November

Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023

Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’

Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published.

Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting

Lytix Biopharma presents first half and second quarter 2023 results

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial

Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase 2 data with LTX-315

Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting

Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023.